Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
Gehling, V.S., Hewitt, M.C., Vaswani, R.G., Leblanc, Y., Cote, A., Nasveschuk, C.G., Taylor, A.M., Harmange, J.C., Audia, J.E., Pardo, E., Joshi, S., Sandy, P., Mertz, J.A., Sims, R.J., Bergeron, L., Bryant, B.M., Bellon, S., Poy, F., Jayaram, H., Sankaranarayanan, R., Yellapantula, S., Bangalore Srinivasamurthy, N., Birudukota, S., Albrecht, B.K.(2013) ACS Med Chem Lett 4: 835-840
- PubMed: 24900758 
- DOI: https://doi.org/10.1021/ml4001485
- Primary Citation of Related Structures:  
4LR6, 4LRG - PubMed Abstract: 
The identification of a novel series of small molecule BET inhibitors is described. Using crystallographic binding modes of an amino-isoxazole fragment and known BET inhibitors, a structure-based drug design effort lead to a novel isoxazole azepine scaffold. This scaffold showed good potency in biochemical and cellular assays and oral activity in an in vivo model of BET inhibition.
Organizational Affiliation: 
Constellation Pharmaceuticals , 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States.